Luteolin Inhibits hyperglycemia-induced proinflammatory cytokine production and its epigenetic mechanism in human monocytes

Phytotherapy Research

Volumn 28, Issue 9, 2014, Pages 1383-1391

  Kim, Hye Joo ^a   Lee, Wooje ^b   Yun, Jung Mi ^c  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Kwangju Women University   (South Korea)

Author keywords

Acetylation; Deacetylation; Luteolin; NF B; p300

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LUTEOLIN; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, HUMAN; GLUCOSE; HISTONE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY TEST; DEACETYLATION; DOWN REGULATION; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; EPIGENETICS; GENE; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IL 6 GENE; INTRACELLULAR SIGNALING; MONOCYTE; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TNF ALPHA GENE; UPREGULATION; ACETYLATION; CELL LINE; CHEMISTRY; CULTURE MEDIUM; GENETIC EPIGENESIS; METABOLISM; NF-ΚB; P300; SIGNAL TRANSDUCTION;

ACETYLATION; DEACETYLATION; LUTEOLIN; NF-ΚB; P300;

ACETYLATION; CELL LINE; CULTURE MEDIA; E1A-ASSOCIATED P300 PROTEIN; EPIGENESIS, GENETIC; GLUCOSE; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INTERLEUKIN-6; LUTEOLIN; MONOCYTES; NF-KAPPA B; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907927150     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5141     Document Type: Article

References (69)

1. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N. 2000. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 130: 2243-50.
2. Ashburner BP, Westerheide SD, Jr Baldwin AS. 2001. The p65 (RelA) subunit of NF-kB interacts with the histone deactylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065-7077.
3. Barnes J, Karin M. 1997. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071.
4. Baynes JW. 1991. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412.
5. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 787-790.
6. Chen CY, Peng WH, Tsai KD, Hsu SL. 2007. Luteolin suppresses inflammation-associated gene expression by blocking NFkappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci 81: 1602-1614.
7. Chen LF, Mu Y, Greene WC. 2002. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 21: 6539-6548.
8. Cheung WL, Briggs SD, Allis CD. 2000. Acetylation and chromosomal functions. Curr Opin Cell Biol 12: 326-333.
9. Cooper ME, El-Osta A. 2010. Epigenetics: mechanisms and implications for diabetic complications. Circ Res 107: 1403-1413.
10. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. 2007. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 99: 15-26.
11. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. 2006. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55: 774-779.
12. Devaraj S, Cheung AT, Jialal I, et al. 2007. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56: 2790-2796.
13. El-Bassossy HM, Abo-Warda SM, Fahmy A. 2013. Chrysin and Luteolin Attenuate Diabetes-Induced Impairment in Endothelial-Dependent Relaxation: Effect on Lipid Profile, AGEs and NO Generation. Phytother Res 27: 1678-1684.
14. El-Osta A, Brasacchio D, Yao D, et al. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normorglycemia. J Exp Med 205: 2409-2417.
15. Fotsis T, Pepper MS, Montesano R, et al. 1998. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 12: 649-666.
16. Funakoshi-Tago M, Nakamura K, Tago K, Mashino T, Kasahara T. 2011. Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin. Int Immunopharmacol 11: 1150-1159.
17. Grunstein M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389: 349-352.
18. Gerritsen ME, Williams A J, Neish AS, Moore S, Shi Y, Collins T. 1997. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 94: 2927-2932.
19. Gray SG, De Meyts P. 2005. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 21: 416-433.
20. Guha M, Bai W, Nadler J, Natarajan R. 2000. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stressdependent and -independent pathways. J Biol Chem 275: 17728-17739.
21. Hanneken A, Lin FF, Johnson J, Maher P. 2006. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci 47: 3164-3177.
22. Habtemariam S. 2013. Antihyperlipidemic components of Cassia auriculata aerial parts: identification through in vitro studies. Phytother Res 27: 152-155.
23. Hirano T, Higa S, Arimitsu J, et al. 2004. Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int Arch Allergy Immunol 134: 135-140.
24. Ho E, Clarke JD, Dashwood RH. 2009. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 139: 2393-2396.
25. Igarashi M, Wakasaki H, Takahara N, et al. 1999. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 103: 185-195.
26. Jang S, Kelley KW, Johnson RW. 2008. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A 105: 7534-7539.
27. Jain SK, Rains J, Croad J, Larson B, Jones K. 2009. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 11: 241-249.
28. Kang GL. 2008. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 79: 1527-1534.
29. Kim HY, Jung SK, Byun S, et al. 2013. Raf and PI3K are the Molecular Targets for the Anti-metastatic Effect of Luteolin. Phytother Res 27: 1481-1488.
30. Kim SH, Shin KJ, Kim D, et al. 2003. Luteolin inhibits the nuclear factor-kappa B transcriptional activity in Rat-1 fibroblasts. Biochem Pharmacol 66: 955-963.
31. Kiernan R, Brès V, Ng RW, et al. 2003. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758-2766.
32. Kurdistani SK, Grunstein M. 2003. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4: 276-284.
33. López-Lázaro M. 2009. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9: 31-59.
34. Link A, Balaguer F, Goel A. 2010. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol 80: 1771-1792.
35. Lin L, Li Y, Tollefsbol TO. 2008. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 10: 25-36.
36. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. 2013. Diabetes Mellitus and inflammation. Curr Diab Rep 13: 435-44.
37. Lousia M, Natarajan R. 2010. Epigenetics of diabetic complications. Expert Rev Endocrinol Metab 5: 137-148.
38. Maher PA. 2006. Comparison of the neurotrophic activities of the flavonoid luteolin and some of its derivatives. Free Radic Res 40: 1105-1111.
39. Miao F, Gonzalo IG, Lanting L, Natarajan R. 2004. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 279: 18091-18097.
40. Moghaddam G, Ebrahimi SA, Rahbar-Roshandel N, Foroumadi A. 2012. Antiproliferative activity of flavonoids: influence of the sequential methoxylation state of the flavonoid structure. Phytother Res 26: 1023-1028.
41. Morimoto T, Sunagawa Y, Kawamura T, et al. 2008. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118: 868-878.
42. Mukaida N. 2000. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 72: 391-398.
43. Muller S, Martin S, Koenig W. 2002. Impaired glucose tolerance is associated with increased serum concentrations of interlukin 6 and co-regulated acute proteins but not TNF-alpha or its receptors. Diabetologia 45: 805-812.
44. Navarro JF, Mora C. 2005. Role of inflammation in diabetic complications. Nephrol Dial Transplant 20: 2601-2604.
45. Navarro-Gonzalez JF, Mora-Fernandez C. 2008. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-442.
46. Nishikawa T, Edelstein D, Du XL, et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404: 787-790.
47. Perkins ND. 2006. Post-translational modifications regulating the activity and function of the nuclear factor κB pathway. Oncogene 25: 6717-6730.
48. Pugliese G, Tilton RG, Williamson JR. 1991. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 7: 35-59.
49. Rahman A, Fazal F. 2011. Blocking NF-κB: an inflammatory issue. Proc Am Thorac Soc 8: 497-503.
50. Rahman I, Marwick J, Kirkham P. 2004. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol 15: 1255-1267.
51. Romano B, Pagano E, Montanaro V, Forunato AL, Milic N, Borrelli F. 2013. Novel insights into the Pharmacology of Flavonoids. Phytother Res 27: 1588-1596.
52. Roth SY, Denu JM, Allis CD. 2001. Histone acetyltransferases. Annu Rev Biochem 70: 81-120.
53. Ross JA, Kasum CM. 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22: 19-34.
54. Ruderman N, Williamson JR, Brownlee M. 1992. Glucose and diabetic vascular disease. FASEB J 6: 2905-2914.
55. Schmid H, Boucherot A, Yasuda Y, et al. 2006. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55: 2993-3003.
56. Shanmugam N, Reddy MA, Guha M, Natarajan R. 2003. Highglucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52: 1256-1264.
57. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. 2002. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 45: 151.
58. Thompson PR, Wang D, Wang L, et al. 2004. Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 11: 308-315.
59. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. 1999. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 274: 32091-32098.
60. Wang GG, Lu XH, Li W, Zhao X, Zhang C. 2011. Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats. Evid Based Complement Alternat Med 2011: 323171. doi: 10.1155/2011/323171.
61. Wolfram S. 2007. Effects of Green Tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 26: 373S-388S.
62. Wu CH, Wu CF, Huang HW, Jao YC, Yen GC. 2009. Naturally occurring flavonoids attenuate high glucose-induced expression of proinflammatory cytokines in human monocytic THP-1 cells. Mol Nutr Food Res 53: 984-995.
63. Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C. 2001. Luteolin inhibits an endotoxinstimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 96: 181-187.
64. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. 1999. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307-27314.
65. Yan SF, Ramasamy R, Schmidt AM. 2008. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4: 285-293.
66. Yeung F, Hoberg JE, Ramsey CS, et al. 2004. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2360-2380.
67. Yun JM, Chien A, Jialal I, Devaraj S. 2011a. Resveratrol upregulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 23: 699-705.
68. Yun JM, Jialal I, Devaraj S. 2011b. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem 22: 450-458.
69. Zhong H, Voll RE, Ghosh S. 1998. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1: 661-671.